Results 81 to 90 of about 408 (149)

P12.08 Immunocytokines are a novel immunotherapeutic approach against glioblastoma

, 2019
BACKGROUND Glioblastoma is the most common malignant primary brain tumor in adults with an urgent need for novel treatment options. The administration of pro-inflammatory cytokines could be a potent immunotherapeutic approach to shift ...
Roth, P, Weiss, T, Neri, D, Weller, M, Puca, E   +4 more
core   +1 more source

Antibody-based delivery of interleukin-2 modulates the immunosuppressive tumor microenvironment and achieves cure in pancreatic ductal adenocarcinoma syngeneic mice

Journal of Experimental & Clinical Cancer Research
Background Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive and deadly type of cancer, with an extremely low five-year overall survival rate.
Carmine Carbone, Roberto De Luca, Emanuele Puca, Antonio Agostini, Alessia Caggiano, Lorenzo Priori, Annachiara Esposito, Serena Ascrizzi, Geny Piro, Lisa Salvatore, Francesco De Sanctis, Stefano Ugel, Vincenzo Corbo, Dario Neri, Giampaolo Tortora   +14 more
doaj   +1 more source

Miniaturized IL-2/anti-IL-2 immunocytokines selectively activate and support the in vivo persistence of regulatory T cells

Frontiers in Immunology
IntroductionInterleukin-2 (IL-2) is a multifunctional cytokine that potently expands regulatory T cells (Tregs) and thus has potential in mitigating autoimmune diseases and promoting transplant tolerance.
Charina S. Fabilane, Charina S. Fabilane, Jakub Tomala, Paul M. Zdinak, Paul M. Zdinak, Paul M. Zdinak, Bailey T. Chalmers, Bailey T. Chalmers, Bailey T. Chalmers, A. Carson Stephenson, A. Carson Stephenson, Emily Ariail, Emily Ariail, Ella C. Teeley, Alok V. Joglekar, Alok V. Joglekar, Alok V. Joglekar, Jamie B. Spangler, Jamie B. Spangler, Jamie B. Spangler, Jamie B. Spangler, Jamie B. Spangler, Jamie B. Spangler, Jamie B. Spangler, Jamie B. Spangler   +24 more
doaj   +1 more source

A novel strategy to generate immunocytokines with activity-on-demand using small molecule inhibitors

EMBO Molecular Medicine
Cytokine-based therapeutics have been shown to mediate objective responses in certain tumor entities but suffer from insufficient selectivity, causing limiting toxicity which prevents dose escalation to therapeutically active regimens. The antibody-based
Giulia Rotta, Ettore Gilardoni, Domenico Ravazza, Jacqueline Mock, Frauke Seehusen, Abdullah Elsayed, Emanuele Puca, Roberto De Luca, Christian Pellegrino, Thomas Look, Tobias Weiss, Markus G Manz, Cornelia Halin, Dario Neri, Sheila Dakhel Plaza   +14 more
doaj   +1 more source

Targeting FAP/CAFs to rewire immune-excluded and resistant tumor niches

Frontiers in Pharmacology
Immune checkpoint blockade (ICB) has reshaped cancer therapy, yet many solid tumors remain immune-excluded, with cytotoxic T cells trapped in stromal regions and unable to access malignant nests.
Yingying Wang, Yajun Zhao, Ce Zhou, Yang Wang   +3 more
doaj   +1 more source

Teaching an old dog new tricks : activity-on-target interferon to treat T-cell acute lymphoblastic leukemia [PDF]

, 2020
Background Type 1 interferon (IFN) has a long history in the treatment of cancer, including hematological malignancies. The anti-cancer effects induced by IFN result from a combination of 1) direct cancer cell growth inhibition by cell cycle arrest ...
Van Vlierberghe, Pieter, Goossens, Steven, Pieters, Tim, Daneels, Willem, Tavernier, Jan, Cauwels, Anje   +5 more
core  

Rewiring tumor cytokine networks to enhance immune checkpoint blockade: mechanisms, engineering, and clinical translation

Journal of Experimental & Clinical Cancer Research
Immune checkpoint inhibitors (ICIs) targeting PD-1/PD-L1 and CTLA-4 can produce durable remissions in multiple solid tumors, yet primary and acquired resistance remain frequent, often sustained by an immunosuppressive tumor microenvironment (TME ...
Xiaodong Wang, Junjie Wang, Qianqian Wang, Gouping Ding, Yiping Huang, Yeqian Feng   +5 more
doaj   +1 more source

Contemporary Approaches to In-Transit Melanoma

, 2018
In-transit melanoma represents a distinct disease pattern of heterogeneous superficial tumors. Many treatments have been developed specifically for this type of disease, including regional chemotherapy and a variety of directly injectable agents.
Douglas S. Tyler, Jennifer A. Perone, Georgia M. Beasley, Nellie Farrow   +3 more
core   +1 more source

The Evolving Role of Intralesional Therapy in In-Transit Melanoma

Current Oncology
In-transit melanoma represents a biologically aggressive form of locoregional disease in which effective management requires integration of local tumor control with systemic immune engagement. Although traditional regional therapies achieve high response
Celine Jeun, Mackenzie M. Mayhew, Kate Joshua, Russell G. Witt   +3 more
doaj   +1 more source

A safe and highly efficient tumor-targeted type I interferon immunotherapy depends on the tumor microenvironment

OncoImmunology, 2018
Despite approval for the treatment of various malignancies, clinical application of cytokines such as type I interferon (IFN) is severely impeded by their systemic toxicity.
Anje Cauwels, Sandra Van Lint, Geneviève Garcin, Jennyfer Bultinck, Franciane Paul, Sarah Gerlo, José Van der Heyden, Yann Bordat, Dominiek Catteeuw, Lode De Cauwer, Elke Rogge, Annick Verhee, Gilles Uzé, Jan Tavernier   +13 more
doaj   +1 more source